Cancer is a leading cause of morbidity and mortality, accounting for nearly one third of all deaths, prompt investigation, diagnosis and treatment is more likely to ensure better outcomes for cancer patients.
In our Eighth o2h ChaiTime webinar we discussed how we can speed up translating basic cancer research into new cancer therapeutics to get drugs to the front-line more quickly.
Artios ($84M Series B financing) to develop drugs for novel targets in the DNA Damage Repair pathway. Prior to Artios, Niall was co-founder of Mission Therapeutics.
Recently joined Apple Tree Partners ($2.5B under management) with an amazing career that spans positions spearheading cancer therapeutics, Celgene, AZ and the Institute of Cancer Research (San Diego, Boston, London).
PhoreMost is dedicated to first-in-class targets and focuses on drugging “Undruggable” targets.
Ruth has a huge amount of experience at bringing oncology drugs through the clinic, she is the Director of the Sir Bobby Robson Cancer trials Research Centre with responsibility for early phase trials practice.
Professor of Cancer Research, University of Cambridge & Emeritus Director, Medical Research Council Cancer Unit, Director-designate, Cancer Science Institute of Singapore.